Table 2.

Patient risk factors, disease status, and medication in the low-Lp(a) and high-Lp(a) groups.

Risk factors/ vascular diseases	Overall	Low-Lp(a) group	High-Lp(a) group	p
Participants	850			0.001
ASCVD patients	533	75.8% (n = 404)	24.2% (n = 129)
Healthy controls	317	85.2% (n = 270)	14.8% (n = 47)
CAD	332	36.8% (n = 246)	50% (n = 86)	0.004
PAD	409	45.8% (n = 308)	57.7% (n = 101)	0.004
CAD and PAD				0.004
CAD and PAD yes	215	22.9% (n = 153)	35.4% (n = 62)
CAD only	118	13.9% (n = 93)	14.3% (n = 25)
PAD only	194	23.2% (n = 155)	22.3% (n = 39)
CAD and PAD no	316	40% (n = 267)	28% (n = 49)
CeVD	91	9.2% (n = 60)	17.6% (n = 31)	0.007
Diabetes mellitus	198	23.5% (n = 158)	22.7% (n = 40)	0.920
Hypertension	600	70.1% (n = 472)	72.7% (n = 128)	0.250
Heart failure	460	53.2% (n = 352)	72.8% (n = 108)	0.014
Myocardial infarction	136	13.9% (n = 92)	24.7% (n = 43)	0.001
Smoking				0.728
Current smoker	164	20.7% (n = 132)	18.7% (n = 32)
Ex-smoker	210	25.4% (n = 162)	28.1% (n = 48)
Never	436	54% (n = 345)	53.2% (n = 91)
Medication	Overall	Low-Lp(a) group	High-Lp(a) group	p
ACEis	263	29.8% (n = 201)	35.2% (n = 62)	0.171
Anticoagulation	165	19% (n = 128)	21% (n = 37)	0.593
ARBs	245	28.3% (n = 191)	30.7% (n = 54)	0.575
Beta-blockers	372	40.7% (n = 274)	55.7% (n = 98)	0.001
Clopidogrel	100	10.1% (n = 68)	18.2% (n = 32)	0.005
Diuretics (alodosterone)	31	3.6% (n = 24)	4% (n = 7)	0.821
Ezetimibe	63	5.5% (n = 37)	14.8% (n = 26)	0.001
PCSK9i	4	0.3% (n = 2)	1.1% (n = 2)	0.191
P2Y12 inhibitors	122	12.6% (n = 85)	21% (n = 37)	0.008
Rivaroxaban	96	10.5% (n = 68)	18.4% (n = 28)	0.039
Statins	451	50.4% (n = 340)	63.1% (n = 111)	0.003